Cumberland's multicenter study supports Vaprisol Injection

Cumberland Pharmaceuticals Inc.'s open label multicenter study, published in Drug Design, Development and Therapy, supports the efficacy and use of Vaprisol Injection for treating hyponatremic patients with severe hepatic impairment.
Hyponatremia, an electrolyte disturbance involving low sodium ion concentration in blood plasma, is seen in a variety of critical care conditions, including liver cirrhosis.
According to Cumberland, The open label multicenter study – published in March – joins a growing body of literature supporting Vaprisol. In hyponatremic patients suffering from severe hepatic impairment, the study notes, treatment should start with a loading dose of 10 mg given intravenously, followed by infusions of 10 mg per day for two to four days.
“With reported incidences of hyponatremia in hospitalized cirrhosis patients being greater than 50%, the opportunity to treat hyponatremic patients inflicted with various degrees of hepatic impairment is high,” Cumberland CEO A.J. Kazimi said in a statement. “There is much information and experience supporting the use of Vaprisol as a safe and well-tolerated treatment, and these study results support Cumberland’s mission to provide effective treatment options that help address the unmet medical needs.”